Eying growth in oncology, Astellas has suffered an R&D setback for acute myeloid leukemia drug Xospata (gilteritinib). The med flunked a combo trial with Bristol …
Eying growth in oncology, Astellas has suffered an R&D setback for acute myeloid leukemia drug Xospata (gilteritinib). The med flunked a combo trial with Bristol …
While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …
After the FDA slapped an updated safety warning on marketed oral JAK inhibitors for inflammatory diseases, market watchers have started worrying about other candidates in …
Some of Amgen’s key businesses are drawing concerns as competition looms. Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry …
Bristol Myers Squibb has expanded Opdivo’s first-in-class win in pre-surgery non-small cell lung cancer, teeing up a potential FDA filing. Opdivo added to chemotherapy before …
It wasn’t long ago that Bristol Myers Squibb ran the numbers on potentially buying Acceleron Pharma, but that deal didn’t come together, and the biotech …
Bristol Myers Squibb’s new corporate campaign celebrates transformation—of science, the pharma industry and patients’ lives. It’s the pharma’s first corporate campaign since BMS’ own transformation …
Bristol Myers Squibb boasts a historic go-ahead for Opdivo plus chemotherapy as the first immunotherapy regimen for previously untreated stomach cancer. But the PD-1 inhibitor …
As officials in Washington weigh contentious drug-pricing measures, there’s even more evidence that pharma companies are worried about potential reform. In an open letter to …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
